Loading
SDHA (Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.
Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q). SDH also oxidises malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate. Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerised into keto-oxaloacetate.
CIViC holds 1 clinical evidence item and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.84 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.81, somatic mutation 0.86, genetic literature 0.81). IntOGen calls it a driver in 3 cohorts (2 activating, 0 loss-of-function), covering Chromophobe Renal Cell Carcinoma, Hepatocellular Carcinoma, Low-Grade Glioma, NOS.
In plain words · SDHA (Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.
SDHA (Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.
Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).
No product in this corpus aims at SDHA yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA SDHA: RNA tissue enhanced (heart muscle 522 nTPM, skeletal muscle 447 nTPM); high antibody staining in 15 normal tissues; highest cancer staining liver cancer (4 of 12 high). Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours, Renal cell carcinoma, Hepatocellular carcinoma, Lung cancer (all types), Sarcomas (soft tissue, bone, GIST), Colorectal cancer, Ovarian cancer); Open Targets associates it with 4 specific cancer types at or above 0.5 (pheochromocytoma/paraganglioma syndrome 5, gastrointestinal stromal tumor, hereditary pheochromocytoma-paraganglioma, hereditary neoplastic syndrome). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P31040; CIViC gene SDHA; IntOGen SDHA; Human Protein Atlas SDHA tissue; Open Targets ENSG00000073578 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Malcovati et al, 1991, "Cloning of the flavoprotein subunit of human succinate dehydrogenase". Source.
Sources: HGNC HGNC:10680 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P31040 (protein name, function text, keywords and locations (REST API)); CIViC gene SDHA (1 evidence items, 0 assertions, 2 variants; diseases: Adrenal Gland Pheochromocytoma (GraphQL API, CC0)); Open Targets ENSG00000073578 (association with cancer (MONDO_0004992) 0.84; per-cancer scores at or above 0.5: colorectal cancer 0.51, ovarian cancer 0.50, sarcoma 0.52, neuroendocrine neoplasm 0.84, gastrointestinal stromal tumour 0.74, lung cancer 0.52 (GraphQL API, CC0)); IntOGen SDHA (driver in 3 cohorts (Act 2, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q). SDH also oxidises malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate. Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerised into keto-oxaloacetate. Can act as a tumour suppressor. Location: Mitochondrion inner membrane (UniProt). Locus 5p15.33 (HGNC).
RNA: tissue enhanced (heart muscle 522 nTPM, skeletal muscle 447 nTPM), detected in all normal tissues.
Medium: Appendix, Breast, Caudate, Cerebellum, Cerebral cortex, Cervix, Colon, Endometrium.
Medium only: carcinoid, glioma, head and neck cancer, lung cancer.
HPA SDHA tissue · HPA SDHA pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SDHA" OR ABSTRACT:"SDHA" OR TITLE:"succinate dehydrogenase complex flavoprotein subunit A" OR ABSTRACT:"succinate dehydrogenase complex flavoprotein subunit A" OR TITLE:"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial" OR ABSTRACT:"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial" OR TITLE:"SDH2" OR ABSTRACT:"SDH2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SDHA, not a curated reading list.
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours, Open Targets Platform, Colorectal cancer.
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours, CIViC, Open Targets Platform.
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours, IntOGen, Open Targets Platform.
Shares Gastrointestinal stromal tumour (GIST), Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Gastrointestinal stromal tumour (GIST), Hepatocellular carcinoma, Colorectal cancer.
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST).
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST).
Shares Gastrointestinal stromal tumour (GIST), Sarcomas (soft tissue, bone, GIST).